News | November 14, 2022
Suven Life Sciences posts Q2FY23 consolidated loss at Rs. 23.18 Cr
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
The company has reported total income of Rs. 4.59 crores during the period ended September 30, 2022
R&D center would be doing a lot of new product generation projects, process optimization, scale-up and product life cycle management work, full synthetic labs, the kilo labs, the process safety labs, and the population lab
The company has reported total income of Rs. 77.60 crores during the period ended September 30, 2022
API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories
He has over 23 years' experience working in leading companies such as Omniactive Health Technologies, Johnson Matthey Chemicals, BASF, Godrej Agrovet Limited & Bharat Petroleum Corporation Limited.
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
The proposed acquisition consideration represents an equity value for Myovant of $2.4 billion and an enterprise value of $2.5 billion.
The company will address the observations within a stipulated timeline working with the regulators
Sud has more than 32 years of work experience with different companies like Clivient, Jubilant Life Sciences, Piramal Enterprises, Parabolic Drugs, Orchid Chemicals and Pharmaceuticals, Ranbaxy Labs, and Lupin
Subscribe To Our Newsletter & Stay Updated
